A therapy that retrains the body’s immune system to fight cancer has provoked excitement after more than 90% of terminally ill patients reportedly went into remission.
White blood cells were taken from patients with leukaemia, modified in the lab and then put back.
But the data has not been published or reviewed and two patients are said to have died from an extreme immune response.
Experts said the trial was exciting, but still only “a baby step.”
The news bubbled out of the American Association for the Advancement of Science’s annual meeting in Washington DC.
The lead scientist, Prof Stanley Riddell from the Fred Hutchinson Cancer Research Centre in Seattle, said all other treatments had failed in these patients and they had only two-to-five months to live.
He told the conference that: “The early data is unprecedented.”
In the trial, cells from the immune system called killer t-cells were taken out of dozens of patients. The cells normally act like bombs destroying infected tissue.
The researchers genetically modified the t-cells to engineer a new targeting mechanism – with the technical name of chimeric antigen receptors – to target acute lymphoblastic leukaemia.
Prof Riddell told the BBC: “Essentially what this process does is, it genetically reprograms the T-cell to seek out and recognise and destroy the patient’s tumour cells.
“[The patients] were really at the end of the line in terms of treatment options and yet a single dose of this therapy put more than ninety percent of these patients in complete remission where we can’t detect any of these leukaemia cells.”
But one cancer expert told me they still felt in the dark on the full significance of the study, as the data is not available.
Learn more: Excitement at new cancer treatment
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Immunotherapy could extend survival for patients with aggressive glioblastoma brain cancer on February 19, 2019 at 4:43 am
Sen. John McCain died after a short battle against glioblastoma brain cancer. Glioblastoma — the aggressive brain cancer that killed Sen. John McCain, Sen. Ted Kennedy and Beau Biden, son of ... […]
- Global Cancer Immunotherapy Market is Projected to Reach $170.70 Billion by 2028 on February 19, 2019 at 4:10 am
FREMONT, California, Feb. 19, 2019 /PRNewswire/ -- According to a new market intelligence report by BIS Research, titled "Global Cancer Immunotherapy Market - Analysis and Forecast, 2018-2028", the ma... […]
- Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies on February 19, 2019 at 4:00 am
Emerging clinical data support the combination of angiogenesis inhibitors and immunotherapy to increase effectiveness in multiple cancer indications. 2 Angiogenic factors, such as vascular endothelial ... […]
- Cancer Immunotherapy Drug Discovery Outsourcing Market Worth $1.7 Billion by 2025: Grand View Research, Inc. on February 19, 2019 at 2:52 am
SAN FRANCISCO, Feb. 19, 2019 /PRNewswire/ -- The global cancer immunotherapy drug discovery outsourcing market size is projected to reach USD 1.7Billion by 2025, according to a new report by Grand ... […]
- Global $170+ Bn Cancer Immunotherapy Market to 2028: Focus on Pharmaceutical Products, Therapeutic Indication, Competitive Landscape and Region on February 19, 2019 at 2:45 am
Dublin, Feb. 19, 2019 (GLOBE NEWSWIRE) -- The "Global Cancer Immunotherapy Market: Focus on Pharmaceutical Products, Therapeutic Indication, Competitive Landscape and Region - Analysis and ... […]
- Immunotherapy may help patients with the kind of cancer that killed John McCain on February 18, 2019 at 5:19 pm
Glioblastoma — the aggressive brain cancer that killed Sen. John McCain, Sen. Ted Kennedy and Beau Biden, son of former Vice President Joe Biden — is among the deadliest of cancers, with a three-year ... […]
- Preclinical research finds new approach to treating aggressive cancer on February 17, 2019 at 11:59 pm
However, the benefits are minimal for patients. "While the use of immunotherapy has revolutionized the way we treat lung cancer, we find that small cell lung cancers can escape the immune system ... […]
- Drug combinations could become first-line treatment for metastatic kidney cancer on February 17, 2019 at 9:47 pm
A combination of two drugs - one of them an immunotherapy agent - could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Ca... […]
- Cancer Immunotherapy Market to Hit $117,114 Million by 2022 : Asia-Pacific region is expected to grow with Highest CAGR during forecast period on February 15, 2019 at 11:48 am
Cancer immunotherapy is a type of cancer treatment that boosts the human bodys natural immune system to fight against the cancer cells. This therapy is provided to cancer patients to stop the spread o... […]
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches on February 15, 2019 at 6:16 am
Advances in immunotherapy are improving outcomes for patients with various cancers. In addition, the immunogenicity of breast cancer is leading to increasingly optimistic views on the use of immunothe... […]
via Bing News